Table 5.
Potential drugs targeting VM in clinical trials.
| Drug | Mechanism of action | Condition or disease | Phase | References |
|---|---|---|---|---|
| OKI-179 | HDAC inhibitors | Solid tumor | I | (101) |
| Remetinostat | HDAC inhibitors | Cutaneous T-cell lymphoma | II | (102) |
| Romidepsin | HDAC inhibitors | Cutaneous T-cell lymphoma, peripheral T-cell lymphoma | Launched in 2010 | (103) |
| Panobinostat lactate | HDAC inhibitors | Multiple myeloma | Launched in 2015 | (104) |
| MEN-1611 | PI3K inhibitors | Breast cancer | I | (105) |
| HMPL-689 | PI3Kδ inhibitors | B-cell lymphoma | I | (106) |
| Gedatolisib | PI3K/mTOR inhibitors | Acute myeloid leukemia, solid tumors | II | (107) |
| GDC-0980 | PI3K/mTOR inhibitors | Prostate cancer | II | (108) |
| Buparlisib | PI3K inhibitors | HNSCC | III | (109) |
| Copanlisib hydrochloride | PI3K inhibitors | Lymphoma | Launched in 2017 | (110) |
| siRNA-EphA2-DOPC | EphA2 inhibitors | Solid tumors | I | (111) |